32
Views
2
CrossRef citations to date
0
Altmetric
Miscellaneous

Prostate-specific antigen: a diagnostic marker and a tool for targeted delivery of drugs to prostate tumours

Pages 1035-1046 | Published online: 25 Feb 2005

Bibliography

  • WANG MC, VALENZUELA LA, MURPHY GP, CHU TM: Purification of a human prostate specific antigen. Invest. Urol. (1979) 17(2):159–163.
  • •Discovery of PSA.
  • KURIYAMA M, WANG MC, PAPSIDERO LD et al.: Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res. (1980) 40:4658–4662.
  • WANG MC, PAPSIDERO LD, KURIYAMA M, VALENZUELA LA, MURPHY GP, CHU TM: Prostate antigen: a new potential marker for prostatic cancer. Prostate (1981) 2(0:89–96.
  • VERNON SE, WILLIAMS WD: Pre-treatment and post-treatment evaluation of prostatic adenocarcinoma for prostatic specific acid phosphatase and prostatic specific antigen by immunohistochemistry: J. Ural. (1983) 130(l):95–98.
  • HAMDY FC, LAWRY J, ANDERSON JB, PARSONS MA, REES RC, WILLIAMS JL: Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer. Br. J. Ural. (1992) 69(4):392–396.
  • SCARDINO PT: Early detection of prostate cancer. Urol. Clin. North (1989) 16(4):635–655.
  • EPSTEIN JI, WALSH PC, CARMICHAEL M, BRENDLER CB: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA (1994) 271(5):368–374.
  • OHORI M, WHEELER TM, KATTAN MW GOTO Y, SCARDINO PT: Prognostic significance of positive surgical margins in radical prostatectomy specimens. Urol. (1995) 154(5):1818–1824.
  • ZIETMAN AL, EDELSTEIN RA, COEN JJ, BABAYAN RK, KRANE RJ: Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology (1994) 43(6):828–833.
  • YU H, GIAI M, DIAMANDIS EP, KATSAROS D et al.: Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res. (1995) 55(10):2104–2110.
  • NADJI M, TABEI SZ, CASTRO A et al.:Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms. Cancer (1981) 48(5):1229–1232.
  • PAPSIDERO LD, KURIYAMA M, WANG MC etal.: Prostate antigen: a marker for human prostate epithelial cells. J. Nati Cancer Inst. (1981) 66(0:37–42.
  • QIU SD, YOUNG CY, BILHARTZ DL et al.: In situ hybridization of prostate-specific antigen mRNA in human prostate. J. Ural. (1990) 144(6):1550–1556.
  • CHRISTENSSON A, LAURELL CB, LILJA H: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. Biochern. (1990) 194(3):755–763.
  • LILJA H: A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein: J. Clin. Invest. (1985) 76(5):1899–1903.
  • LILJA H, OLDBRING J, RANNEVIK G, LAURELL CB: Sentinel vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J. Clin. Invest. (1987) 80(2):281–285.
  • MCGEE RS, HERR JC: Human seminal vesicle-specific antigen is a substrate for human prostate-specific antigen (or P-30). Biol. Reprod. (1988) 39(2):499–510.
  • LILJA H, LAURELL CB: Liquefaction of coagulated human semen. Stand. j Clin. Lab. Invest. (1984) 44(5):447–452.
  • MCGEE RS, HERR JC: Human seminal vesicle-specific antigen during semen liquefaction Biol. Reprod. (1987) 37(2):431–439.
  • COHEN P, GRAVES HC, PEEHL DM, KAMAREI M, GIUDICE LC, ROSENFELD RG: Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J. Clin. Endocrinol. Metall. (1992) 75(4):1046–1053.
  • CHRISTENSSON A, BJORK T, NILSSON 0 et al: Serum prostate specific antigen completed to al-antichymotrypsin as an indicator of prostate cancer. j Ural (1993) 150(1):100–105.
  • LILJA H, CHRISTENSSON A, DAHLEN U et al.: Prostate-specific antigen in serum occurs predominantly in complex with aI-antichymotrypsin. Clin. Chem. (1991) 37(9):1618–1625.
  • STENMAN UH, LEINONEN J, ALFTHAN H, RANNIKKO S, TUHKANEN K, ALFTHAN 0: A complex between prostate-specific antigen and al antichymotrypsin I the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. (1991) 51(0:222–226.
  • MAST AE, ENGHILD JJ, PIZZO SV, SALVESEN G: Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase complexed, and reactive site cleaved serpins: comparison of al proteinase inhibitor, al-antichymotrypsin, antithrombin 111, a2-antiplasmin, angiotensinogen, and ovalbuniin. Biochemistry (1991) 30(6):1723–1730.
  • PERLMUTTER DH, GLOVER GI, RIVETNA M, SCHASTEEN CS, FALLON RJ: Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc. Natl. Acad. Sri. USA (1990) 87(10):3753–3757.
  • LILJA H, PIIRONEN TP RITTENHOUSE HG, MIKOLAJCZYK SD, SLAWIN KM: Prostate specific antigen. In: Comprehensive textbook of genitourinary oncology Vogelzang NJ, Shipley VU, Scardino PT, Coffey DS (Eds), Lippincott Williams & Philadelphia: Wilkins Publishers. (2000):638–650.
  • HERRALA A, KURKELA R, VIHINEN M, KALKKINEN N, VIHKO P: Androgen-sensitive human prostate cancer cells, LNCAP, produce both N-terminally mature and truncated prostate-specific antigen isoforms. Eur. j Biochem. (1998) 98:32–33.
  • VEISENEN V, LOVGREN J, HELLMAN J, PIIRONEN T, LILJA H, PETTERSON K: Characterization and processing of prostate-specific antigen (hK3) and human glandular kallikrein 2 (hK2) secreted by LNCAP cells. Prostate Cancer Prostatic Dis. (1999) 2:1–7.
  • KUMAR A, MIKOLAJCZYK SD, HILL TM, MILLAR LS, SAEDI MS: Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen induced LNCaP cells. Prostate (2000) 44:248–254.
  • KUMAR A, MIKOLAJCZYK SD, HILL TM, MILLAR LS, SAEDI MS: Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res. (1997) 50:31–14.
  • TAKAYAMA TK, FUJIKAWA K, DAVIE EW: Characterization of the precursor of prostate- specific antigen. _J. Biol. Chem. (1997) 272:21582–21588.
  • LOVGREN J, RAJAKOSKI K, KARP M,LUND WALL A, LILJA H: Activation of zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem. Biophys. Res. Commun. (1997) 238:549–555.
  • LUND WALL A, LILJA H: Molecular cloning of human prostate specific antigen CDNA: FEBS Lett. (1987) 214(2):317–322.
  • LUND WALL A: Characterization of the gene for prostate-specific antigen, a human glandular kallikrein. Biochem. Biophys. Res. Commun. (1989) 161(3):1151–1159.
  • RIEGMAN PH, VLIETSTRA RJ, VAN DER KORPUT JA, ROMIJN JC, TRAPMAN J: Characterization of the prostate-specific antigen gene: a novel human kallikrein like gene: Biochem. Biophys. Res. Commun. (1989) 159(0:95–102.
  • FORD TF, BUTCHOT DN, MASTERS JR, PARKINSON MC: Immunocytochemical localisation of prostate-specific antigen: specificity and application to clinical practice. Br j Ural (1985) 57(9:50–55.
  • BOWMAN la, CLARK J, YU I et al: Expression, purification and characterization of deglycosylated human pro-prostate specific antigen. Protein Expr. Purif (2000) 20:405–413.
  • LOVGREN J, PIIRONEN T, OVENNO C et al: Production of recombinant PSA and hK2 and analysis of their immunologic cross-reactivity. Biochem. Biophys. Res. Comm. (1995) 213:888–895.
  • PETTERSON K, PIIRONEN T, SEPPALA M et al.: Free and complexed prostate-specific antigen (PSA): In vitro stability, epitope map, and development of immunofluoremetric assays for specific and sensitive detection of free PSA and PSA-al-antichymotrypsin complex. Clin. Chem. (1995) 41:1480–1488.
  • SINHA AA, SACKRISON JL, DELEON OF, WILSON MJ, GLEASON DF: Antibody immunoglobulin G (IgG) against human prostatic specific antigen (PSA) as a carrier protein for chemotherapeutic drugs to human prostate tumors: Part 1. A double immunofluorescence analysis. Anat. Rec. (1996) 245(4):652–661.
  • MCDEVITT MR, BARENDSWAARD E, MA D et al.: An a-particle emitting antibody 4213Bi1J591) for radioimmunotherapy of prostate cancer. Cancer Res. (2000) 60(21):6095–6100.
  • SENTER PD, WALLACE PM, SVENSSON HP et al.: Generation of cytotoxic agents by targeted enzymes. Bioconjug. Chem. (1993) 4(1):3–9.
  • ANTONIW P, SPRINGER CJ, BAGSHAWE KD et al.: Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice. Br. j Cancer (1990) 62(6):909–914.
  • DENMEADE SR, LOU W, LOVGREN J, MALM J, LILJA H, ISAACS JT: Specific and efficient peptide substrates for assaying the proteolytic activity of prostate- specific antigen. Cancer Res. (1997) 57:4924–4930.
  • •Crafting of a specific PSA substrate.
  • DENMEADE SR, NAGY A, GAO J, LILJA H, SCHALLY A, ISAACS JT: Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res. (1998) 58:2537–2540.
  • KHAN SR, DENMEADE SR: In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts. Prostate (2000) 45:80–83.
  • DEFEO-JONES D, GARSKY VM, WONG BK et al.: A peptide-doxorubicin `prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat. Med. (2000) 6 (11):1248–1252.
  • •Crafting of a specific PSA substrate.
  • JAKOBSEN CM, DENMEADE SR, ISAACS JT, GADY A, OLSEN CE, CHRISTENSEN SB: Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apopotosis to prostatic cancer cells. j Med. Chem. (2001) 44:4696–4703.
  • DENMEADE SR, SOKOLL LJ, CHAN DW, KHAN SR, ISAACS JT: Concentration of enzymatically active prostate-specific antigen ( PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate (2001) 48:1–6.
  • FRYDMAN B, MARTON LJ, SUN JS et al.: Induction of DNA topoisomerase II-mediated DNA: cleavage by P-lapachone and related naphthoquinones. Cancer Res. (1997) 57:620–627.
  • DOLAN ME, FRYDMAN B, THOMPSON CB et al: Effects of 1,2-naphthoquinones on human tumor cell growth and lack of cross-resistance with other anticancer agents. Anticancer Drugs (1998) 9:437–448.
  • CHANG SS, REUTER VE, HESTON WD, GAUDIN PB: Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology (2001) 57(6):1179–1183.
  • O'KEEFE DS, UCHIDA A, BACICH DJ et al.: Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate (2000) 45(2):149–157.
  • WILLIAMS-ASHMAN HG, CANELLAKIS ZN: Polyamines in mammalian biology and medicine. Persp. Biol. Med. (1997) 421–453.
  • •A comprehensive review of polyamines and reproduction.
  • FRYDMAN B, VALASINAS A: Polyamine-based chemotherapy of cancer. Expert Opin. Ther. Patents (1999) 9(8):105–168.
  • REDDY VK, VALASINAS A, SARKAR A, BASU HS, MARTON LJ, FRYDMAN B: Conformationally restricted analogues of N1, N12-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. J. Med. Chem. (1998) 41:4723–4732.
  • VALASINAS A, SARKAR A, REDDY VK, MARTON LJ, BASU HS, FRYDMAN B: Conformationally restricted analogues of NI, N14-bisethylhomospermine (BE-4-4-4): synthesis and growth inhibitory effects on human prostate cancer cells. j Med. Chem. (2001) 44(3):390–403. Synthesis of SL–11093.
  • REDDY VK, SARKAR A, VALASINAS A, MARTON LJ, BASU, FRYDMAN B: Cis-Unsaturated analogues of 3,8,13,18,23-pentaazapentacosane (BE-4-4-4-4): Synthesis and growth inhibitory effects on human prostate cancer cell lines. j Med. Chem. (2001) 44(3):404–117.
  • KABRA PM, LEE HK, LUBICH WI MARTON LJ: Solid-phase extraction and determination of dansyl derivatives of unconjugated and acetylated polyamines by reversed-phase liquid chromatography:improved separation systems for polyamines in cerebrospinal fluid, urine, and tissue. j Chromatog. (1986) 380:19–32.
  • COHEN SS: A Guide to the polyamines, Oxford University Press, Oxford, UK. (1998):208–232.
  • ••A comprehensive review on polyamines.
  • BERGERON RJ, WEIMAR WR, LUCHETTA G, SNINSKY CA, WEIGAND J: Metabolism and pharmacokinetics of N1,N14 diethylhomospermine. Drug Metabol Disposition (1996) 24:334–343.
  • •Detailed insight in polyamine metabolism.

Websites

  • AMERICAN CANCER SOCIETY: How many men get prostate cancer? http://www.cancenorg

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.